

South East London Integrated Medicines Optimisation Committee (SEL IMOC)

Withdrawal of position statement 027 (issued Sept 2020):

Preferred choice of methylphenidate modified-release (MR) tablet brand for the treatment of attention deficit hyperactivity disorder (ADHD) in children and in adults (off-label) and for other off-label indications of narcolepsy and idiopathic hypersomnia

Since publication of the original position statement, there are a now number of methylphenidate modified release (MR) branded generic tablets and capsules available. In view of this, the Committee agreed to withdraw this position statement from local use to enable prescribers to switch between the available bioequivalent branded generic products.

The local adult and paediatric formularies have been updated to remove reference to specific brands of methylphenidate modified release tablets and capsules. Removing references to specific brands of methylphenidate MR will support safe and timely access for patients, particularly during periods of supply disruption.

Useful resource links:

- Healthcare professionals can refer to further information on prescribing and switching between modified-release methylphenidate, available from the Specialist Pharmacy Service (SPS) website at:
<https://www.sps.nhs.uk/articles/prescribing-and-switching-between-modified-release-methylphenidate/>.
- The SPS medicines supply tool resource, for NHS healthcare professionals, can be accessed at: <https://www.sps.nhs.uk/home/tools/> (registration required for access).
- The SEL adult joint medicines formulary can be accessed at: <https://selondonjointmedicinesformulary.nhs.uk/default.asp>.
- The SEL joint paediatric medicines formulary can be accessed at: https://app.clinibee.com/publications/d53c53db-7a21-4462-88f1-a34fa1ef7d33/tabs/DEFAULT_PAGE (registration required).

January 2026